PD-L1蛋白与CD8+TILs联合检测在可切除肺腺癌预后评估中的临床意义

doi:10.11904/j.issn.1002-3070.2019.01.007

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (1): 40-46.doi: 10.11904/j.issn.1002-3070.2019.01.007

PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义

马健力¹, 张明辉², 姬宏飞^3,4, 徐向英¹

1.哈尔滨医科大学附属肿瘤医院放射治疗科(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院肿瘤内科;
3.哈尔滨医科大学肿瘤防治研究所;
4.黑龙江省医学科学院

收稿日期:2018-11-12 出版日期:2019-02-28 发布日期:2019-02-13
通讯作者: 徐向英,E-mail:37963326@qq.com
作者简介:马健力,男,(1991-),硕士,主治医师,从事肺癌放射治疗的研究。
基金资助:
黑龙江省自然科学基金(省留学归国人员科学基金)(编号:LC2017037)

Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma

MA Jianli¹, ZHANG Minghui², JI Hongfei^3,4, XU Xiangying¹

1.Department of Radiation Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;
2.Department of Medical Oncology,Harbin Medical University Cancer Hospital;
3.Institute of Cancer Prevention and Treatment,Harbin Medical University;
4.Heilongjiang Academy of Medical Sciences

Received:2018-11-12 Online:2019-02-28 Published:2019-02-13

摘要/Abstract

摘要： 目的 PD-L1表达在可手术切除的肺腺癌(Lung adenocarcinoma,ADC)中的预后作用存在争议,本研究旨在探讨PD-L1联合CD8⁺TILs表达对可切除肺腺癌患者的预后价值。方法选取2009年1月—2012年12月在哈尔滨医科大学附属肿瘤医院接受根治性手术切除的肺腺癌患者104例,免疫组织化学方法检测原发灶标本PD-L1、CD8⁺TILs表达,并分析其临床病理因素及与预后的关系。结果肿瘤细胞中PD-L1阳性表达率为38.5%(40/104),CD8^high TILs的阳性率为44.2%(46/104)。CD8^high TILs与早期可切除ADC患者的TNM分期有关(P=0.021)。生存分析结果显示和CD8^high TILs与无病生存期和总生存期有关,可作为判断可切除ADC患者预后的独立预测因子。结论术后标本PD-L1表达及CD8^high TILs浸润有助于判断患者的预后,该研究对于可手术切除ADC患者中针对PD-1/PD-L1途径的免疫疗法具有一定的指导意义。

关键词: 程序性细胞死亡蛋白-配体1, CD8^highTILs, 肺腺癌, 预后

Abstract: Objective The prognostic role of PD-L1 expression in surgically resected lung adenocarcinoma(ADC)remains controversial.The aim of present study was to investigate the prognostic value of PD-L1 combined with CD8⁺TILs expression in patients with resectable lung adenocarcinoma.Methods A total of 104 patients with lung adenocarcinoma who underwent radical resection were enrolled at the Affiliated Tumor Hospital of Harbin Medical University from January 2009 to December 2012.Immunohistochemistry was used to detect the expression of PD-L1 and CD8⁺TILs in primary tumor specimens.Its clinical pathological factors and its relationship with prognosis were statistical analysis.Results The positive expression rate of PD-L1 in tumor cells was 38.5%(40/104),and the positive rate of CD8⁺TILs was 44.2%(46/104).There was a significant correlation between the expression of CD8⁺TILs and TNM stages of patients with resectable ADC.The Kaplan-Meier survival analysis showed that low expression of PD-L1 and high expression of CD8⁺TILs were significantly associated with disease-free survival(DFS)and overall survival(OS),and could be used as an independent predictors for predicting prognosis of patients with resectable ADC.Conclusion The expression of PD-L1 and CD8⁺TILs in the postoperative specimens can help to judge the prognosis of patients.This study has certain significance for immunotherapy of PD-1/PD-L1 pathway in patients with surgically resected ADC.

Key words: Programmed cell death-ligand 1, CD8^high TILs, Lung adenocarcinoma, Prognosis

中图分类号:

R734.2

马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.

MA Jianli, ZHANG Minghui, JI Hongfei, XU Xiangying. Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 40-46.

参考文献

1 Goldstraw P,Crowley J,Chansky K,et al.The iaslc lung cancer staging project:Proposals for the revision of the tnm stage groupings in the forthcoming(seventh)edition of the tnm classification of malignant tumours[J].J Thorac Oncol,2007,2(8):706-714.
2 Rittmeyer A,Barlesi F,Waterkamp D,et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(Oak):A phase 3,open-label,multicentre randomised controlled trial[J].Lancet,2017,389(10066):255-265.
3 Zhang M,Dong Y,Liu H,et al.The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer:A meta-analysis of 10 studies with 1,901 patients[J].Sci Rep,2016,6:37933.
4 Fridman WH,Pages F,Sautes-Fridman C,et al.The immune contexture in human tumours:Impact on clinical outcome[J].Nat Rev Cancer,2012,12(4):298-306.
5 Brahmer JR,Drake CG,Wollner I,et al.Phase i study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors:Safety,clinical activity,pharmacodynamics,and immunologic correlates[J].J Clin Oncol,2010,28(19):3167-3175.
6 Phelan JD,Young RM,Webster DE,et al.A multiprotein supercomplex controlling oncogenic signalling in lymphoma[J].Nature,2018,560(7718):387-391.
7 Mori H,Kubo M,Yamaguchi R,et al.The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer[J].Oncotarget,2017,8(9):15584-15592.
8 Ness N,Andersen S,Khanehkenari MR,et al.The prognostic role of immune checkpoint markers programmed cell death protein 1(PD-1)and programmed death ligand 1(PD-L1)in a large,multicenter prostate cancer cohort[J].Oncotarget,2017,8(16):26789-26801.
9 Wu S,Shi X,Sun J,et al.The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma[J].Oncotarget,2017,8(10):16421-16429.
10 Ameratunga M,Asadi K,Lin X,et al.PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected nsclc[J].PLoS One,2016,11(4):e0153954.
11 Uruga H,Bozkurtlar E,Huynh TG,et al.Programmed cell death ligand(PD-L1)expression in stage II and III lung adenocarcinomas and nodal metastases[J].J Thorac Oncol,2017,12(3):458-466.
12 Sun JM,Zhou W,Choi YL,et al.Prognostic significance of pd-l1 in patients with non-small cell lung cancer:A large cohort study of surgically resected cases[J].J Thorac Oncol,2016,11(7):1003-1011.
13 Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J].N Engl J Med,2015,373(17):1627-1639.
14 Maleki Vareki S,Garrigos C,Duran I.Biomarkers of response to PD-1/PD-L1 inhibition[J].Crit Rev Oncol Hematol,2017,116:116-124.
15 Huynh TG,Morales-Oyarvide V,Campo MJ,et al.Programmed cell death ligand 1 expression in resected lung adenocarcinomas:Association with immune microenvironment[J].J Thorac Oncol,2016,11(11):1869-1878.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[9]	卞秀森, 李光, 关欣宇, 张伊, 狄畅, 马璨. UHRF1通过调控细胞自噬抑制肺腺癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 498-502.
[10]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[11]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[12]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[13]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[14]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[15]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.

PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义

Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

PD-L1蛋白与CD8+TILs联合检测在可切除肺腺癌预后评估中的临床意义

Clinical significance of combined detection of PD-L1 protein and CD8+TILs in resected lung adenocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义

Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma